⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

May 30, 2024Open Access

Supplemental Figure 1 from Pan-Cancer Interrogation of B7-H3 (CD276) as an Actionable Therapeutic Target Across Human Malignancies

Carly D. Miller John R. Lozada Nicholas A. Zorko Andrew Elliott Allison Makovec Milan Radovich Elisabeth I. Heath Neeraj Agarwal Rana R. McKay Rohan Garje Bruno R. Bastos Dave S.�B. Hoon Jacob J. Orme Oliver Sartor Ari M. Vanderwalde Chadi Nabhan George W. Sledge Eugene Shenderov Scott M. Dehm Emil Lou Jeffrey S. Miller Justin H. Hwang Emmanuel S. Antonarakis

View Full Paper

Ask AI

Bookmark

Share

Abstract

B7-H3 mRNA expression across cancers stratified by age (>/< 65 years old) and sex (male and female)

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Miller et al. (2024) studied this question.

synapsesocial.com/papers/68e67ba3b6db643587605832 https://doi.org/10.1158/2767-9764.25934110.v1

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplemental Figure 1 from Pan-Cancer Interrogation of B7-H3 (<i>CD276</i>) as an Actionable Therapeutic Target Across Human Malignancies2024
2FIGURE 1 from Pan-Cancer Interrogation of B7-H3 (<i>CD276</i>) as an Actionable Therapeutic Target Across Human Malignancies2024
3FIGURE 5 from Pan-Cancer Interrogation of B7-H3 (<i>CD276</i>) as an Actionable Therapeutic Target Across Human Malignancies2024
4FIGURE 4 from Pan-Cancer Interrogation of B7-H3 (<i>CD276</i>) as an Actionable Therapeutic Target Across Human Malignancies2024
5FIGURE 3 from Pan-Cancer Interrogation of B7-H3 (<i>CD276</i>) as an Actionable Therapeutic Target Across Human Malignancies2024